Minapharm Pharmaceuticals's quarterly market cap
increased
from Jun. 2025 (E£2,878 Mil) to Sep. 2025 (E£3,199 Mil) and
increased
from Sep. 2025 (E£3,199 Mil) to Dec. 2025 (E£4,293 Mil).
Minapharm Pharmaceuticals's annual market cap
declined
from Dec. 2023 (E£2,676 Mil) to Dec. 2024 (E£1,996 Mil) but then
increased
from Dec. 2024 (E£1,996 Mil) to Dec. 2025 (E£4,293 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Minapharm Pharmaceuticals's Enterprise Value for Today is E£9,422 Mil.
Minapharm Pharmaceuticals (CAI:MIPH) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Minapharm Pharmaceuticals Market Cap Related Terms
Minapharm Pharmaceuticals Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAI:MIPH vs ZTS, UTHR, VTRS: Market Cap Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Minapharm Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minapharm Pharmaceuticals Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Minapharm Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Minapharm Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Minapharm Pharmaceuticals (CAI:MIPH) has a Market Cap of E£8,224 Mil as of Jul. 13, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Minapharm Pharmaceuticals and its competitors. According to the industry distribution chart, Minapharm Pharmaceuticals ranks #551 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 53.8%.
Is Minapharm Pharmaceuticals' Market Cap too high?
Minapharm Pharmaceuticals' current Market Cap is E£8,224 Mil. Based on the distribution chart, Minapharm Pharmaceuticals ranks #551 out of 1024 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Minapharm Pharmaceuticals has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Minapharm Pharmaceuticals ranks #551 out of 1024 companies for Market Cap. This places Minapharm Pharmaceuticals in the lower half of its industry. The industry median Market Cap is 212.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 212.63, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Minapharm Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Market Cap is 212.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minapharm Pharmaceuticals's current Market Cap is E£8,224 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£362.31, compared to a current price of E£698.08 — trading 92.7% above its estimated fair value. The current Market Cap is E£8,224 Mil. Minapharm Pharmaceuticals' overall GF Score™ is 41/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current Market Cap is E£8,224 Mil as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued.
The current stock price of E£698.08 is trading 92.7% above its estimated GF Value™ of E£362.31.
GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CAI:MIPH:
Market Cap: E£8,224 Mil
GF Value™: E£362.31 vs. price of E£698.08 (92.7% above fair value)
No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
41GF Score
Get the complete analysis for CAI:MIPH
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:MIPH has been successfully added to your 
